Home / Health / One-Time Gene Edit Could Erase Bad Cholesterol
One-Time Gene Edit Could Erase Bad Cholesterol
19 Aug
Summary
- New gene therapy permanently disables cholesterol-producing gene.
- Single infusion lowered bad cholesterol by 62% for 18 months.
- Potential future treatment for lifelong cholesterol control.
A revolutionary gene therapy from Eli Lilly and Verve Therapeutics is showing immense promise in permanently reducing LDL cholesterol. The experimental treatment, VERVE-102, involves a single intravenous infusion designed to switch off the PCSK9 gene in the liver.
This innovative approach targets the root cause of high cholesterol by altering DNA, aiming for a 'one-and-done' solution. Early trial results indicate a significant LDL reduction of 62% that persisted for at least 18 months, a stark contrast to traditional daily medications.
While VERVE-102 is still in clinical testing and requires further large-scale data, it represents a potential future for managing cardiovascular risk. Experts suggest it may eventually be considered for high-risk patients, particularly those with familial hypercholesterolemia.
The long-term implications of this permanent genetic modification are still under investigation. However, the success of naturally occurring PCSK9 gene mutations in reducing heart disease offers a promising outlook for this novel therapy.
